Copyright © 2002 by the European Society of Cardiology.
Editorials
Surrogate markers to monitor efficacy of anticoagulants or antiplatelet drugs in atrial fibrillation
Department of Clinical Pharmacology, Vienna University, Vienna, Austria
References
- Kamath S, Blann AD, Chin BSP. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J. 2002;23:17881795
[Abstract/Free Full Text] - Pernerstorfer T, Stohlawetz P, Stummvol G. Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haematol. 1998;102:12291231[CrossRef][Web of Science][Medline]
- Kamath S, Blann AD, Lip GY. Platelets and atrial fibrillation. Eur Heart J. 2001;22:22332242
[Free Full Text] - Ganz DA, Lamas GA, Orav EJ. Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators. J Am Geriatr Soc. 1999;47:145150[Web of Science][Medline]
- Loebstein R, Yonath H, Peleg D. Interindividual variability in sensitivity to warfarinnature or nurture? Clin Pharmacol Ther. 2001;70:159164[CrossRef][Web of Science][Medline]
- Hollenstein U, Homoncik M, Knöbl P. Acenocoumarol decreases tissue factor dependent coagulation during systemic inflammation in humans. Clin Pharmacol Ther. 2002;71:368374[CrossRef][Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||